Literature DB >> 36159202

Effectiveness and Safety of Early Short-Course, Moderate- to High-Dose Glucocorticoids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Retrospective Study.

Zhenzhen Ye1, Chunting Li1, Hua Zhang2, Chunlei Zhang1, Xueyan Lu1.   

Abstract

Objective: To summarise the clinical characteristics of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis syndrome (SJS/TEN) and analyse the efficacy and safety of systemic glucocorticoid therapy.
Methods: This study was a retrospective study of 56 patients with SJS/TEN who had been systematically treated with glucocorticoids in the dermatology ward of Peking University Third Hospital from 2010 to 2020. The clinical characteristics, treatment regimen, effects on underlying diseases, incidence and outcome of hormone-related adverse reactions and skin lesion prognosis were summarised and analysed for each patient.
Results: ① The allergenic drugs were found to be antibiotics (31.51%), antipyretic and analgesics (21.92%), traditional Chinese medicines and health products (15.07%) and neuropsychiatric drugs (13.70%). ② Based on the 56 patients' scores of toxic epidermal necrosis at admission, the actual mortality rate was 1.8% (1/56), which was significantly lower than the average expected mortality rate of 15.0% (P = 0.032; standardised mortality ratio = 0.13; 95% confidence interval: 0.00-0.53). ③ A total of 33 patients (58.9%) had underlying diseases, of which 10 patients (30.3%) had underlying diseases that fluctuated during treatment but stabilised after symptomatic treatment. ④ During treatment, 73.2% (41/56) of patients had complications that may have been related to systemic glucocorticoids; 97.6% (40/41) had mild symptoms, and 92.7% (38/41) had improved/recovered complications at the time of discharge.
Conclusion: ① Antibiotics are still the most common sensitising drugs, and traditional Chinese medicine and health products are also common sensitising drugs. ② Early systemic application of medium- to high-dose glucocorticoids is effective in the treatment of SJS/TEN, and it is beneficial in reducing mortality. ③ The short-term application of medium- to high-dose hormone therapy for SJS/TEN has little effect on underlying diseases. The related complications are mostly mild, and the treatment is safe.
© 2022 Ye et al.

Entities:  

Keywords:  SCORTEN; Stevens–Johnson syndrome; glucocorticoid-related complications; toxic epidermal necrolysis; treatment

Year:  2022        PMID: 36159202      PMCID: PMC9504527          DOI: 10.2147/CCID.S378106

Source DB:  PubMed          Journal:  Clin Cosmet Investig Dermatol        ISSN: 1178-7015


  22 in total

1.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Jui-Yung Yang; Shih-Chi Su; Shien-Ping Huang; Chun-Yu Wei; See-Wen Chin; Chien-Chun Chiou; Sung-Chao Chu; Hsin-Chun Ho; Chih-Hsun Yang; Chi-Fang Lu; Jer-Yuarn Wu; You-Di Liao; Yuan-Tsong Chen
Journal:  Nat Med       Date:  2008-11-23       Impact factor: 53.440

2.  Stevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors.

Authors:  Vamsee K Neerukonda; Anna M Stagner
Journal:  Semin Ophthalmol       Date:  2021-03-25       Impact factor: 1.975

3.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY.

Authors:  Yehuda Handelsman; Zachary T Bloomgarden; George Grunberger; Guillermo Umpierrez; Robert S Zimmerman; Timothy S Bailey; Lawrence Blonde; George A Bray; A Jay Cohen; Samuel Dagogo-Jack; Jaime A Davidson; Daniel Einhorn; Om P Ganda; Alan J Garber; W Timothy Garvey; Robert R Henry; Irl B Hirsch; Edward S Horton; Daniel L Hurley; Paul S Jellinger; Lois Jovanovič; Harold E Lebovitz; Derek LeRoith; Philip Levy; Janet B McGill; Jeffrey I Mechanick; Jorge H Mestman; Etie S Moghissi; Eric A Orzeck; Rachel Pessah-Pollack; Paul D Rosenblit; Aaron I Vinik; Kathleen Wyne; Farhad Zangeneh
Journal:  Endocr Pract       Date:  2015-04       Impact factor: 3.443

4.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.

Authors:  Khosrow S Houschyar; Christian Tapking; Mimi R Borrelli; Behrus Puladi; Mark Ooms; Christoph Wallner; Dominik Duscher; Dominik Pförringer; Susanne Rein; Georg Reumuth; Torsten Schulz; Ina Nietzschmann; Zeshaan N Maan; Gerrit Grieb; Wolfgang G Philipp-Dormston; Ludwik K Branski; Frank Siemers; Marcus Lehnhardt; Laurenz Schmitt; Amir S Yazdi
Journal:  J Wound Care       Date:  2021-12-02       Impact factor: 2.072

5.  Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study.

Authors:  Khalaf Kridin; Marie-Charlotte Brüggen; Ser-Ling Chua; Anette Bygum; Sarah Walsh; Mirjam C Nägeli; Vesta Kucinskiene; Lars French; Florence Tétart; Biagio Didona; Brigitte Milpied; Annamari Ranki; Carmen Salavastru; Eva Brezinová; Sapna Divani-Patel; Tine Lorentzen; Julie Loft Nagel; Skaidra Valiukeviciene; Viktorija Karpaviciute; George-Sorin Tiplica; Eva Oppel; Anna Oschmann; Nicolas de Prost; Artem Vorobyev; Saskia Ingen-Housz-Oro
Journal:  JAMA Dermatol       Date:  2021-10-01       Impact factor: 11.816

6.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors:  Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal:  J Invest Dermatol       Date:  2007-09-06       Impact factor: 8.551

7.  Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies.

Authors:  J Wu; Y Y Lee; S C Su; T S Wu; K C Kao; C C Huang; W C Chang; C H Yang; W H Chung
Journal:  Br J Dermatol       Date:  2015-10-19       Impact factor: 9.302

8.  The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018.

Authors:  Yuma Sunaga; Michiko Kurosawa; Hirotaka Ochiai; Hideaki Watanabe; Hirohiko Sueki; Hiroaki Azukizawa; Hideo Asada; Yuko Watanabe; Yukie Yamaguchi; Michiko Aihara; Yoshiko Mizukawa; Manabu Ohyama; Natsumi Hama; Riichiro Abe; Hideo Hashizume; Saeko Nakajima; Takashi Nomura; Kenji Kabashima; Mikiko Tohyama; Hayato Takahashi; Hiroki Mieno; Mayumi Ueta; Chie Sotozono; Hiroyuki Niihara; Eishin Morita; Akatsuki Kokaze
Journal:  J Dermatol Sci       Date:  2020-09-28       Impact factor: 4.563

Review 9.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 10.  Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Lin Cheng
Journal:  Front Pharmacol       Date:  2021-04-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.